Influence of tissue graft substitute in the treatment of gingival recessions

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
12/08/2024		[X] Protocol		
Registration date	Overall study status Ongoing	Statistical analysis plan		
21/08/2024		Results		
Last Edited	Condition category Oral Health	[] Individual participant data		
19/08/2025		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

The treatment of multiple adjacent gingival recessions in teeth with interproximal attachment loss is probably one of the most challenging situations in the field of periodontal plastic surgery. Furthermore, usually, this clinical condition is combined with reduction of keratinized tissue and vestibulum depth. Several surgical approaches have been proposed to treat these recessions with heterogeneous results. Recently, scientific literature has reported that an apical buccal access flap combined with an autologous connective tissue graft could be a successful surgical design. Nevertheless, the quantity of connective tissue grafts for multiple adjacent gingival recessions is high and the use of different substitutes as acellular dermal matrixes is associated with lower patient morbidity. The study aims to evaluate the clinical effects and patient perceptions of the use of an acellular dermal matrix combined with apical buccal access flap in terms of complete root coverage, reduction of the recession or percentage of coverage and changes in volumetric terms, keratinized tissue width and thickness and patient perception and reported measurements.

Who can participate?

Adult patients presenting multiple adjacent gingival recessions with interproximal attachment loss

What does the study involve?

In this study, participants are randomly assigned to different treatment groups to test whether a new treatment works better than the current one or a placebo. The study follows the participants over time to see how they respond and has a follow-up of 12 months. Participants will be treated with an apical buccal flap and acellular dermal matrix (test) or autologous connective tissue graft (control).

What are the possible benefits and risks of participating? Benefits

1. Advancement of Medical Knowledge:

Participation in this study will contribute to the growing knowledge regarding the efficacy and safety of different techniques for treating gingival recessions. This can lead to improved treatment protocols and better patient outcomes in the future.

2. Access to Innovative Treatments:

Participants may receive a novel treatment with a soft tissue substitute that could offer benefits such as reduced morbidity, less postoperative discomfort, and quicker recovery times compared to traditional connective tissue grafts.

3. Close Monitoring and Care:

Being part of a clinical study often entails regular and comprehensive follow-up care. Participants will benefit from detailed monitoring of their oral health, which may result in earlier detection and management of any potential complications.

4. Improvement of Aesthetic and Functional Outcomes:

Participants may experience improved aesthetic and functional outcomes, including enhanced gingival contour and coverage, as well as potential reductions in tooth sensitivity.

Risks

1. Uncertain Outcomes:

The nature of the soft tissue substitute means that its long-term effectiveness and safety are not fully established. Participants may face a higher risk of graft failure, insufficient root coverage, or other unforeseen complications.

2. Surgical Risks:

As with any surgical procedure, there are inherent risks including bleeding, pain, swelling, and infection. These risks are present in both the experimental and control groups, though they may vary in severity depending on the treatment received.

3. Postoperative Discomfort:

The soft tissue substitute, while potentially less invasive, may still result in postoperative discomfort. Participants undergoing the connective tissue graft may experience more significant discomfort due to the harvesting of tissue from the palate.

4. Study-Specific Protocol Risks:

Adherence to study protocols may require participants to follow strict postoperative care instructions, attend multiple follow-up visits, and undergo additional assessments, which could be time-consuming and burdensome.

Where is the study run from? Clínica Ortiz-Vigón Periocentrum Research Bilbao

When is the study starting and how long is it expected to run for? January 2023 to July 2027

Who is funding the study?
Arrow Research Development SL

Who is the main contact?
Mr Aitor Rilo, aitor@ortizvigon.com

Contact information

Type(s)Scientific

Contact name

Mr Aitor Rilo

ORCID ID

https://orcid.org/0009-0001-0316-1593

Contact details

Alameda Urquijo no 2 - 7a planta Bilbao Spain 48008 +34 944158902 aitor@ortizvigon.com

Type(s)

Principal investigator

Contact name

Mr Alberto Ortiz-Vigón

ORCID ID

https://orcid.org/0000-0002-1863-5907

Contact details

Alameda Urquijo no 2 - 7a planta Bilbao Spain 48008 944158902 alberto@ortizvigon.com

Type(s)

Public

Contact name

Mr Erik Regidor

ORCID ID

https://orcid.org/0000-0003-3338-6379

Contact details

Alameda Urquijo no 2 - 7a planta Bilbao Spain 48008 944158902 erik@ortizvigon.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Treatment of multiple adjacent gingival recessions with interproximal attachment loss with an acellular dermal matrix and apical buccal access. Randomized clinical trial

Study objectives

The use of an acellular dermal matrix in the treatment of multiple adjacent gingival recessions in teeth with attachment loss reduces the patient morbidity, and surgical intervention time and offers non-inferior clinical outcomes in terms of complete coverage of the recession, percentage of coverage or reduction of the recession, increase of keratinized tissue thickness and width and volumetric changes.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 31/07/2023, Ethical Committee of the Basque Country (CEIm de Euskadi [Comité de Ética de la Investigación Clínica con medicamentos] Farmaziako Zuzendaritza / Dirección de Farmacia. Osasun saila / Departamento de Salud. Eusko Jaurlaritza / Gobierno Vasco (C/ Donostia- San Sebastián, Vitoria-Gasteiz, 01010, Spain; +34 945 01 64 59; ceic.eeaa@euskadi. eus), ref: PS2023042

Study design

Prospective randomized clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Multiple adjacent gingival recessions with interproximal attachment loss

Interventions

The study will be a prospective randomized clinical trial with a follow-up of 12 months. Patients presenting multiple adjacent gingival recessions with interproximal attachment loss (RT3 from Cairo et al 2011 Classification) will be treated with an apical buccal flap and acellular dermal

matrix (test) or autologous connective tissue graft] (control) randomly. The randomization and treatment allocation to the experimental and control groups will be performed using sealed envelopes.

- Control group: treatment of gingival recessions with apical buccal access flap/ approach and autologous connective tissue graft].
- Test group: treatment of gingival recessions with apical buccal access flap/approach and acellular dermal matrix

Intervention Type

Procedure/Surgery

Primary outcome(s)

Complete coverage of the recession measured using a periodontal probe, intra-oral scanning file (STL) and digital software overlapping different files at 6 and 12 months

Key secondary outcome(s))

- 1. Esthetic score measured using using numeric values from 0 to 10 at 6 months and 1 year
- 2. Patient-reported postoperative pain measured using a VAS scale at 2 weeks
- 3. Patient satisfaction measured using a VAS scale at 1 year
- 4. Keratinized tissue width (KTW) gain measured in mm using a manual periodontal probe at 6 months and 1 year
- 5. Keratinized tissue thickness (KTT) measured in mm using an intra-oral scanning file (STL) and digital software at 6 months and 1 year
- 6. Professional-reported esthetics measured by a blinded examiner using numeric values from 1 to 5 at 6 months and 1 year

Completion date

15/07/2027

Eligibility

Key inclusion criteria

- 1. Patients ≥ 18 years old
- 2. Periodontally and systemically healthy
- 3. Patients presenting multiple (at least 2) adjacent gingival recessions with interproximal a9achment loss RT3 gingival recessions from Cairo et al 2011 Classification, including gingival recessions in upper and lower maxilla from premolar to premolar area.
- 4. Full mouth plaque score and full mouth bleeding score ≤ 20% (measured at four sites per tooth)
- 5. The patient must be able to perform food oral hygiene

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Contraindications for periodontal surgery or systemically unhealthy
- 2. Patients pregnant or attempting to get pregnant
- 3. Uncontrolled periodontal disease
- 4. Gingival recessions in the molar area
- 5. Single gingival recession

Date of first enrolment

28/08/2024

Date of final enrolment

28/08/2025

Locations

Countries of recruitment

Spain

Study participating centre

Clínica Ortiz-Vigón Periocentrum Research Bilbao

Avenida Urquijo 2, Planta 7

Bilbao

Spain

48008

Sponsor information

Organisation

Arrow Research Development SL

Funder(s)

Funder type

Industry

Funder Name

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Mr Aitor Rilo, aitor@ortizvigon.com

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file			19/11/2024	No	No